+/-mice/Cadherin gene/Tumor suppressor gene. p53 is one of the most frequently mutated genes in mammary carcinomas (MCs). To detect tumor suppressor genes cooperating with a hetero-deficient p53 gene in mammary carcinogenesis, we first examined allelotypes in MCs from (BALB/cHeA × MSM/Ms) F1-p53 +/-and (BALB/cHeA × 129/SvEv) F1-p53 +/-female mice, and then surveyed down-regulated genes in the allelic loss regions. Genome-wide screening at 42 loci identified frequent (more than 30%) loss of heterozygosity (LOH) on chromosomes 5, 8, 11, 12, 14 and 18 in the MCs from either of the F1 mice. The MCs in the p53 +/-mice indicated highly frequent LOH, especially on chromosomes 8, 11 and 12, distinct from other mouse tumors. More than 60% of the 38 MCs from (BALB/cHeA × MSM/Ms) F1-p53 +/-mice showed LOH in a region ranging from D8Mit85 (105.0 Mb from centromere) to D8Mit113 (111.8 Mb) on chromosome 8, a region syntenic to human chromosome 16q22.1, on which LOH has been found in breast cancers. RT-PCR analyses revealed that the LOH of chromosome 8 was associated with the reduced and/or complete loss of expression of Cdh1 and Cdh5 genes in 15 (58%) and 8 (31%) of 26 MCs derived from the F1 mice, respectively. Thus, inactivation of Cdh1 and Cdh5 is likely to cooperate with the loss of p53, suggesting a possible tumor suppressive function of these genes in mammary carcinogenesis.
INTRODUCTION
A number of studies have been performed to clarify the molecular mechanism underlying the development of breast cancer. The p53 gene is mutated in approximately 50% of human cancers 1, 2) and sporadic breast cancers show a high frequency of p53 mutations. 3) In fact, the frequency of p53 mutations varies from 20 to 40% in breast cancers, depending on the tumor size and the stage of the disease. 4) Li-Fraumeni syndrome is due to germline mutations of p53, and patients are predisposed to a high incidence of breast cancer, sarcomas and other neoplasms. 5, 6) Loss of function of p53, by both genetic and epigenetic changes, is thus crucial in mammary carcinogenesis. In addition, some other genetic events are required for the development of mammary carcinomas (MCs) since the carcinogenesis is multi-step. In fact, analyses of knockout (KO) mice revealed that Brca1 and Brca2 tumor suppressor genes cooperate with p53. 7, 8) Studies of transgenic mice also indicated that neu, Wnt1, ras and IGF-1 oncogenes also cooperate with p53 to accelerate tumor formation. 9) Furthermore, p53 mutations are highly frequent in breast cancers of those patients carrying germline mutations of BRCA1 or BRCA2. 10, 11) In p53-heterozygous deficient BALB/c mice (BALB/c-p53 +/-), almost all MCs exhibit a loss of the remaining wild-type p53 allele. 12) As the function of p53 is completely lost in these MCs, additional genetic events related to other tumor suppressor genes can be detected by analyses of allelotypes and alterations of gene expression in the tumors.
Various genetic events result in a loss of heterozygosity (LOH) in cancers, 13) and the LOH regions often contain tumor suppressor genes in human and in experimental animals. 14, 15) Therefore, the genome-wide search for the tumor suppressor genes can be made by allelotype analysis in F1 hybrid mice between two different subspecies, 16, 17) 
Atm
+/-mice. Then, the regions with LOH were analyzed for the down-regulated genes for possible genes cooperating with the loss of p53 for the development of MCs. We found that highly frequent LOH appeared on chromosomes 8, 11 and 12 in the MCs. The LOH of a region of chromosome 8 was found to be associated with the reduced and/or complete loss of expression of the Cdh1 and Cdh5 genes.
MATERIALS AND METHODS

Mice
The p53 targeted allele originally generated by Donehower et al. 18) was introduced into the BALB/cHeA mouse at The Netherlands Cancer Institute (Amsterdam). The p53-heterozygous deficient mice (p53 +/-) were repeatedly backcrossed to BALB/cHeA mice, and maintained at the animal facility of Osaka Prefecture University. The MSM/Ms mice used in the production of F1 mice in this study were Atmheterozygous deficient mice (MSM/Ms-Atm +/-). The Atm targeted mouse (129/SvEv-Atm tm1Awb/+ mouse) was originally generated at the Jackson Laboratory. 19) The Atm-heterozygous deficient mice (Atm +/-) were repeatedly backcrossed more than ten times to MSM/Ms mice. The BALB/cHeAp53 +/-mice were crossed with MSM/Ms-Atm +/-or 129SvEv-Atm +/-mice, and females of the F1 progeny [(BALB/cHeA × MSM/Ms)F1 and (BALB/cHeA × 129SvEv)F1] were used in the experiments. The conditions for breeding were described previously. 20) All animal experiments were carried out in accordance with the Standards Relating to the Care and Management of Experimental Animals (Japan) and the Guidelines for Animal Care and Use of Osaka Prefecture University.
Induction of MC and histological examination
Mice with genotypes of p53
Atm +/-were exposed to 5Gy X-rays at five weeks of age. MCs arising in the irradiated mice were used in the present study. Additional 11 MCs were those from non-irradiated F1 mice with the same genotypes. Developed MCs and normal tissues were removed, and immediately frozen and kept at -80°C until isolation of DNA and RNA. Histological examination was described previously. 21) Briefly, the tissues were fixed in 10% neutralized formalin solution and embedded in paraffin. Thin sections were prepared from the paraffin blocks. They were stained with hematoxylin and eosin for microscopic examination.
DNA isolation, LOH analysis and genotyping
Isolation of DNA, PCR amplification, electrophoresis of PCR products and the assessment of allelic losses were performed according to the procedures described previously. 20) The chromosomal locations (cM) of the microsatellite markers were based on the 2000 Chromosome Committee Reports in the Mouse Genome Database (Mouse Genome Informatics; Jackson Laboratory, Bar Harbor, ME). The chromosomal locations (Mb) of the markers and genes were based on Ensemble and UCSC databases. Genotypes for the wild-type and targeted alleles of p53 and Atm genes were determined by analyzing the PCR products for these alleles. Amplification of the p53 alleles was described elsewhere. 22) Similarly, amplification of the wild-type and the targeted allele of the Atm gene were performed by using primers IMR0640 (5'-GCTGCCATACTTGATCCATG-3') and IMR-0641 (5'-TCCGAATTTGCAGGAGTTG-3'), and primers IMR0641 and AtmNeo410 (5'-CGGTGGATGTGGAAT-GTGTG-3'), respectively.
Expression analysis of the Cadherin family by RT-PCR
The tissues were stored in RNAlater RNA Stabilization Reagent (QIAGEN). Total RNA was isolated from the tissues using RNeasy Protect Mini Column Kit (QIAGEN) as recommended by the manufacturer. cDNA was synthesized using SUPERSCRIPT II Amplification Kit (Invitrogen). The reaction volumes were 50 μl and the reaction tubes contained SUPERSCRIPT TM reverse transcriptase/Platinum taq DNA polymerase (1 μl), dNTPs (0.2 mM of each), magnesium sulfate (1.2mM) and gene specific sense/anti-sense primers (0.2 μM) at concentrations that were recommended by the manufacturer. The primers for RT-PCR of cadherin family members are shown as below. 
Exon analysis of Cdh5 gene
Tumor and normal tissue DNA were amplified using the primer sets for each exon as described below. Sequences of the primers were designed using a software Primer 3 based on DNA sequences shown on NCBI Sequence Viewer. Reverse: CCTAGATGATGAGTTCCTCCTG The PCR conditions consisted of 3 min at 94°C, followed by 35 cycles of a denaturation step of 1 min at 94°C, an annealing step of 1min at 58°C, an extension step of 75 sec at 72°C, and a final extension step of 3 min at 72°C. +/-mice at 42 polymorphic microsatellite loci. Fig. 1A depicts the highest frequency of LOH found in the analyses of 2 to 4 loci on each chromosome. In (BALB/cHeA × MSM/Ms) F 1 -p53 +/-, highly frequent allelic losses were found at D8Mit270 (56 cM from centromere) on chromosome 8, D11Mit12 (75.4 cM) on chromosome 11 and D12Nds1 (27 cM) on chromosome 12, and the frequencies of LOH at these loci were 52%, 57% and 65%, respectively. LOH of lower frequencies was observed at several loci; 26% at D3Mit6 (23.3 cM), 22% at D4Mit13 (71 cM), 30% at D5Mit81 (28 cM), 20% at D9Mit20 (61 cM), 28% at D10Nds2 (58 cM), 35% at D14Mit7 (44.7 cM), 26% at D16Mit7 (57.7 cM) and 22% at D18Mit8 (47 cM) (Fig. 1A) .
RESULTS
Genome-wide search for LOH in MCs from
LOH analysis was then performed for 13 MCs from 5 Gyirradiated (BALB/cHeA × 129SvEv)F1-p53 +/-mice at 42 polymorphic microsatellite loci. Fig. 1B demonstrates the highest frequency of LOH at 1 to 4 loci on each chromosome. Highly frequent LOH was again found on chromosome 8 at D8Mit87 (56 cM), on chromosome 11 at D11Mit51 (15 cM) near p53 and on chromosome 12 at D12Mit132 (52 cM), and the frequencies of LOH at these loci were 92%, 92% and 77%, respectively. LOH with a lower frequencies was observed in several loci; 23% at D4Mit31 (51 cM), 23% at D6Mit55 (50 cM), 23% at D10Nds1 (6 cM), and 31% at D18Mit8 (47 cM) (Fig. 1B) .
Thus, more than 30% LOH was observed in MCs on chro- Fig. 2 ).
Among the loci tested, the highest frequency of LOH was found at two loci, and the frequency was 68% (26 of 38 MC) (Fig. 2) . One was D8Mit212 (107.0 Mb, 51 cM), which is a 
Inactivation of cadherin (Cdh) family genes
D8Mit212, one of the two loci exhibiting the most frequent LOH, is a marker within the Cdh5 gene. Other members of the cadherin family, such as Cdh1, Cdh3, Cdh8, Cdh11 and Cdh16, are also located in the frequent LOH region. The consequence of LOH was tested by analyzing the expression of these cadherin genes, Cdh1, Cdh3, Cdh5, Cdh8, Cdh11 and Cdh16, which exist in the chromosomal region syntenic to human chromosome 16q22.1, on 26 MCs from (BALB/cHeA × MSM/Ms) F 1 -p53 +/-mice. Representative examples of RT-PCR of cadherin mRNA are shown in Fig. 3 . Expression of the Cdh1 and Cdh5 genes was not detected in 15 (58%) and 8 (31%) of the 26 tumors, respectively (Fig. 4) . The expression of Cdh3 and Cdh8 mRNA was also absent in 4 (15%) and 7 (27%) of the 26 tumors, respectively (Fig. 4) . No inactivation of Cdh11 and Cdh16 genes was observed.
The integrity of all 11 exons of the Cdh5 gene was examined by PCR of DNA segments with primers designed within each exon in the 8 tumors in which down-regulation of Cdh5 was observed by RT-PCR. PCR products of exon 7, 8 or 10 were not detected in 4 of 8 tumors (data not shown). Thus, abnormality of some of the exons of the Cdh5 gene was found to be associated with the loss of expression in MCs arising in p53 +/-mice. 
Frequent LOH on chromosomes 12
Since frequent LOH extended to some loci on chromosome 12 in genome-wide screening described earlier, precise allelotype analysis on chromosome 12 was also examined for 28 radiation-induced MCs from (BALB/cHeA × MSM/ Ms) F1-p53 +/-mice (Fig. 5) . Highly frequent LOH was found at many loci throughout chromosome 12. Two regions are of particular interest; a wide region from D12Mit37 (1 cM) to D12Mit30 (46 cM) and a near telomeric region centered at D12Mit279 (53 cM). No strain preference for the allelic loss was observed on this chromosome.
DISCUSSION
p53 is one of the most frequently mutated genes in MC. However, the MC development in p53 +/-mice is greatly modified by genetic background. Mammary tumors develop at less than 1% of all tumors in p53 +/-mice of the 129/Sv and C57BL/6 × 129/Sv backgrounds. 25) In contrast, the p53-heterozygotes of the BALB/c genetic background spontaneously develop mammary tumors at a high incidence. 12, 26, 27) In addition, the mammary epithelia of BALB/c-p53 -/-mice develop into mammary tumors at high incidence when transplanted into mammary fat pads of p53 +/+ BALB/c hosts. 28) Thus, genetic components cooperating with the p53 deficiency must be present in BALB/c to promote mammary tumor formation. In the analysis of N2 backcross mice [(C57BL × BALB/c) × BALB/c], BALB/c alleles for Prkdc and Cdkn2a do not bring about a difference in mammary tumor susceptibility. 29) Thus, the BALB/c genetic components remain to be elucidated. Therefore, the search for allelic loss in MC from F 1 -p53 +/-mice heterozygous with the BALB/c were carried out to find some tumor suppressor genes cooperating with both p53 +/-and the BALB/c genetic components in mammary carcinogenesis.
By genome-wide LOH screening, we found highly frequent LOH on chromosomes 8, 11 and 12 (Fig. 1) . The wildtype allele of p53 on chromosome 11 was lost in almost all the MCs from p53 +/-mice (data not shown), and so LOH at the p53 locus was nearly 100%. A considerable portion of the LOH found on chromosome 11 is thought to accompany the loss of the p53 wild allele. Therefore, important tumor suppressor genes cooperating with homozygously deficient p53 gene and the BALB/c genetic components in the mammary carcinogenesis are expected to reside in the regions of LOH of chromosomes 8 and 12. In these allelic loss regions, one allele of the recessive tumor suppressor genes can be inactivated by methylation, base substitutions or microdeletions. The other allele can be subsequently lost by the mechanisms operating at the chromosome level such as large rearrangements due to mitotic recombination. 30) Although the effect of X-irradiation on tumorigenesis is partially changed by genetic background, 31) highly frequent LOH on chromosomes 8 and 12 were found in MCs from two different F 1 -p53 +/-mice. More than 60% of the MCs showed LOH in a region rang- (Fig. 4) . Inactivation of CDH1, a tumor suppressor gene, has been reported in many human breast cancers. 36, 37) On the other hand, the expression pattern of Cdh5 (VE-cadherin) was more complex. Cdh5 expression is up-regulated in invasive breast carcinomas which contributes for neovascularization of the tumors.
38) VE-cadherin was exclusively expressed by highly aggressive melanoma cells and yet it was undetectable in the poorly aggressive tumor cells, suggesting the difference in ability to induce tumor angiogenesis. 39) In contrast, the endothelial specific VE-cadherin is low or absent in angiosarcomas, suggesting an inhibitory role for this protein in tumor progression. 40) In MCs from (BALB/c × MSM)F1-p53 +/-mice, the expression of Cdh5 gene was not detected in 8 (31%) of the 26 tumors showing LOH on chromosome 8 (Fig. 4) . Furthermore, exons 7, 8 or 10 of Cdh5 failed to be amplified in 4 of the 8 MCs, indicating some impairment of the gene.
The overexpression of CDH3 (P-cadherin) in breast cancer is strongly associated with tumor aggressiveness, and the aberrant expression might be regulated by hypomethylation of gene prompoter region. 41) In the present analyses, expression of Cdh3 mRNA was absent in only a few MCs from the F1 mice with BALB/c-p53 +/-mice (Fig. 4) . Screening of 16 cell lines from renal cell carcinomas revealed a complex pattern of cadherin expression, and cadherin 8 may be involved in tumorigenesis in some types of renal cell carcinomas. 42) The expression of Cdh8 mRNA was absent in 7 (27%) of the 26 tumors in our study (Fig. 4) . These discrepancies between the previous reports and our study remain to be clarified in further studies. Cdh11 mRNA and protein are expressed in the most invasive cell lines but not in any of the noninvasive cell lines, suggesting that the Cdh11 expression may well correlate with the invasive phenotype in cancer cells. 43) Inactivation of Cdh11 and Cdh16 genes was not observed in our study.
Another highly frequent LOH on chromosome 12 was observed in at least two regions; a wide region from D12Mit37 (1 cM) to D12Mit30 (46 cM) and at D12Mit279 (53 cM) which is close to the telomeric region. The former region is very large, and may contain more than one tumor suppressor gene. However, no major tumor suppressor gene has been reported yet in this region of MC. The latter region contains Rit1 (Bcl11b), a major tumor suppressor gene found in mouse thymic lymphomas. 44, 45) Future studies on the role of this gene in mammary carcinogenesis are likely to yield important insight of the mechanism of radiation-induced mammary carcinogenesis.
Our genome-wide screening at 42 loci identified frequent LOH (more than 30%) in chromosomes 5 (D5Mit81, 28 cM), 11 (D11Mit12, 75.4 cM), 14 (D14Mit7, 44.7 cM) and 18 (D18Mit8, 47 cM) in addition to chromosomes 8 and 12. The use of KO mice indicated that Brca1 (60.5 cM on chromosome 11) and Brca2 (88 cM on chromosome 5) cooperate with p53. 7, 8) Another tumor suppressor gene, Rb1, is located at 41 cM on chromosome 14. However, the contribution of the Brca1, Brca2 and Rb1 genes to tumor development in the BALB/c-p53 +/-mice remains to be determined.
